Denali Therapeutics Inc. Common Stock — 四半期決算報告書 (NASDAQ:DNLI) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

Market Capitalization 3.4383 B
Employee 503
Founded 2013
CEO N/A
Website www.denalitherapeutics.com
Headquarter Delaware, United States
FIGI BBG008P7F869
Industry Technology

総売上高

当期純利益

1株当たり基本利益（基本EPS）

有利子負債合計

フリーキャッシュフロー

現金および現金同等物

3.44 B 時価総額

ニュース

Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow (NASDAQ:DNLI) 2026-03-27

Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up

FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript

Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript

Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?

FDA高官の退任で希少疾患関連株が上昇とStifelが指摘

Stifel sees rare disease stocks gaining after FDA official exit

Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript

ジェフリーズ、遺伝子治療の見通しを受けてDenali株の買い推奨を継続